MONTREAL, Dec. 06, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for the Company’s intravenous (IV) push form of administration of Trogarzo®. The IV Push Trogarzo® program continues the Company’s commitment to improving the lives and treatment outcomes for patients living with HIV. Read More
Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV
